Website maintenance is planned from 8:00 a.m. CDT Saturday, July 27, through 9:00 p.m. CDT Sunday, July 28. Brief disruptions may occur during this time.
Monitoring of glucose levels and maintaining adequate glycemic control for gestational diabetes are paramount to decreasing adverse outcomes, including stillbirth. If nutritional modification and glucose monitoring alone control maternal glycemic status such that pharmacological therapy is not required, the risk of stillbirth due to uteroplacental insufficiency is not increased. Thus, the use of routine antepartum testing (e.g., biophysical profile or nonstress test) in the absence of other comorbidities is not indicated.